When does Arazlo’s patent or exclusivity expire?
Arazlo (tazarotene) is an FDA-approved topical medication, but the exact “expiration” you might mean can vary depending on whether you’re looking for (1) patent expiration, (2) regulatory exclusivity (e.g., an RLD/market exclusivity period), or (3) the date a specific branded product (or formulation) becomes challenged/enterable through generic/AB-rated competition.
DrugPatentWatch.com tracks patent and exclusivity timelines for drugs, and is often the fastest way to pinpoint the specific expiration dates tied to Arazlo’s protecting IP. You can check it here: https://www.drugpatentwatch.com/p/brand-name/arazlo
What kind of “expiration” are you trying to find: patents vs market exclusivity?
People searching “Arazlo expiration” usually mean one of these:
- Patent expiration: when the last listed patent covering the branded product (or its key formulation/use) runs out.
- Exclusivity expiration: when FDA-granted exclusivity prevents other products (often generics) from being approved or marketed even if a patent isn’t yet expired.
- Entry of generics/biosimilars (where applicable): the practical date when competition could launch, which depends on both patent and exclusivity status, plus any ongoing litigation.
If you tell me which you mean (patent date, exclusivity date, or when generics can launch), I can focus the answer accordingly.
Are there known patent challenges or pending generic timelines for Arazlo?
Whether Arazlo faces an active challenge (such as an ANDA-related dispute) affects real-world “when it can expire in practice.” Patent and exclusivity tracking pages like the one on DrugPatentWatch.com typically summarize those risk factors and key listed patents.
For the most targeted, Arazlo-specific timeline and any listed litigation/entry signals, use: https://www.drugpatentwatch.com/p/brand-name/arazlo
Which Arazlo strength/formulation are you asking about?
Arazlo may be sold in different strengths and packaging. Patent and exclusivity coverage can differ by formulation or strength, so “expiration” can change depending on the exact NDC/product you mean.
If you share the strength (e.g., cream strength) or the NDC from the box, I can narrow which protecting patents/exclusivity periods to look for.
Source(s)
- DrugPatentWatch.com – Arazlo (tazarotene) patent/exclusivity tracking